First Manhattan CO Alkermes Plc. Transaction History

First Manhattan CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 12, 2019	SELL	$28.4 - $36.49 $23.8 Million - $30.6 Million	-837,894 Reduced 99.88%	1,000 $36,000
Q4 2018 Jan 30, 2019	BUY	$27.94 - $44.61 $7.9 Million - $12.6 Million	282,900 Added 50.88%	838,894 $24.8 Million
Q3 2018 Oct 15, 2018	BUY	$38.6 - $46.12 $21.4 Million - $25.6 Million	554,994 Added 55499.4%	555,994 $23.6 Million
Q3 2017 Oct 25, 2017	BUY	$49.16 - $54.45 $49,160 - $54,450	1,000	1,000 $50,000

363

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.67B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.